Researcher
Xavier Saelens
- Keywords (Ghent University):antiviral immunity, virology, vaccines
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Applied immunology, Drug discovery and development not elsewhere classified, Clinical trials, Biopharmaceuticals, In vitro testing, Non-clinical studies, Animal immunology, Transcription and translation, Vaccines, Molecular and cell biology not elsewhere classified, Virology
Affiliations
- Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2018 → Today - Saelens Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Jan 1996 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Jan 1993 → 31 Dec 1995
Projects
1 - 10 of 45
- New antivirals against human parainfluenza virusFrom1 Apr 2023 → TodayFunding: IOF - technology validation in lab
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolutionFrom1 Jan 2022 → TodayFunding: FWO EOS
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammationFrom1 Oct 2021 → TodayFunding: BOF - projects
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseasesFrom1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- Generation of potent, broadly betacoronavirus neutralizing antibody constructsFrom1 Nov 2020 → 31 Oct 2022Funding: FWO Strategic Basic Research Grant
- Designed, broadly protective antibodies directed against influenza B.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- mRNA Lipid nanoparticles co-loaded with alpha-Galactosylceramide as a universal influenza vaccine platformFrom1 Oct 2020 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Prophylaxis of at risks persons with an ultrapotent SARS-CoV-2-neutralizing antibodyFrom22 May 2020 → 31 May 2021Funding: FWO Special Call for Covid-19 research projects
Publications
1 - 10 of 155
- GlycoVHH : optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery(2023)
Authors: Loes van Schie, Wander Van Breedam, Charlotte Roels, Bert Schepens, Martin Frank, Ahmadreza Mehdipour, Bram Laukens, Wim Nerinckx, Francis Santens, Simon Devos, et al.
- Development of digital droplet PCR targeting the influenza H3N2 sseltamivir-resistant E119V mutation and its performance through the use of reverse genetics mutants(2023)
Authors: Laura Van Poelvoorde, François E. Dufrasne, Steven Van Gucht, Xavier Saelens, Nancy H. C. Roosens
Pages: 2521 - 2532 - Proteomic data and structure analysis combined reveal interplay of structural rigidity and flexibility on selectivity of cysteine cathepsins(2023)
Authors: Livija Tušar, Jure Loboda, Francis Impens, Piotr Sosnowski, Emmy Van Quickelberghe, Robert Vidmar, Hans Demol, Koen Sedeyn, Xavier Saelens, Matej Vizovišek, et al.
- Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B(2023)
Authors: João Portela Catani, Tine Ysenbaert, Anouk Smet, Marnik Vuylsteke, Thorsten U. Vogel, Xavier Saelens, Victor C. Huber
- ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection(2022)
Authors: Mohammad Arabpour, Cristina Lebrero-Fernandez, Karin Schön, Anneli Strömberg, Vanja Börjesson, Katharina Lahl, Marlies Ballegeer, Xavier Saelens, Davide Angeletti, William Agace, et al.
Pages: 745 - 761 - Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies(2022)
Authors: Teodora-Eugenia Oltean, Lorena Ibanez, Tatyana Divert, Tine Ysenbaert, Hannelore Van Eeckhoutte, Vera Goossens, Michael Schotsaert, Ken Bracke, Bert Schepens, Jonathan Maelfait, et al.
- Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells(2022)
Authors: Anouk Smet, João Portela Catani, Tine Ysenbaert, Amanda Gonçalves, Harry Kleanthous, Thorsten U. Vogel, Xavier Saelens, Emma Job, Sander Herfst
- A general approach to identify low-frequency variants within influenza samples collected during routine surveillance(2022)
Authors: Laura Van Poelvoorde, Thomas Delcourt, Marnik Vuylsteke, Sigrid C. J. De Keersmaecker, Isabelle Thomas, Steven Van Gucht, Xavier Saelens, Nancy Roosens, Kevin Vanneste
- Cov²MS : an automated and quantitative matrix-independent assay for mass spectrometric measurement of SARS-CoV-2 nucleocapsid protein(2022)
Authors: Bart Van Puyvelde, Katleen Van Uytfanghe, Laurence Van Oudenhove, Ralf Gabriels, Tessa Van Royen, Arne Matthys, Morteza Razavi, Richard Yip, Terry Pearson, Nicolas Drouin, et al.
Pages: 17379 - 17387 - An unexpected encounter : respiratory syncytial virus nonstructural protein 1 interacts with mediator subunit MED25(2022)
Authors: Tessa Van Royen, Koen Sedeyn, Georgios Moschonas, Wendy Toussaint, M Vuylsteke, Delphi Van Haver, Francis Impens, Sven Eyckerman, Irma Lemmens, Jan Tavernier, et al.
Patents
1 - 8 of 8
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- Anti-influenza antibody (Inventor)
- RESPIRATORY SYNCYTICAL VIRUS VACCINE (Inventor)
- SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN (Inventor)
- CORONA VIRUS BINDERS (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)